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Until recent decades, sickle cell disease (SCD) was associated
with recurrent., disabling pain, organ failure and death in child-
hood or early adulthood. SCD treatment advances have now
decreased pain and prolonged survival, but episodic or chron-
ic pain may still require substantial analgesic use and frequent
hospitalization for pain episodes. This pain is poorly character-
ized and often poorly treated. Adult patients may face barriers
to comprehensive SCD care, sligmatization of the care-seek-
ing behavior by providers and lack of family support, forcing
them into maladaptive coping strategies.
The Pain in Sickle Cell Epidemiology Study (PiSCES) attempts to
develop and validate a biopsychosocial model of SCD pain,
pain response and healthcare utilzafion in a large, multisite adult
cohort. PiSCES participants complete a baseline survey and six
months of daily pain diaries in which they record levels of SCD-
related pain and related disability and distress as well as respons-
es to pain (e.g., medication use, hospital visits).
PiSCES will advance methods of measuring pain and pain
response in SCD by better describing home-managed as well as
provider-managed pain. PiSCES will assess the relative contribu-
lions of biological (disease-related), psychosocial and environ-
mental (readiness to utilize) factors to overall pain and pain
response in SCD, suggesfing targets for biobehavioral interven-
tions over ime. Importantly, PiSCES will also identify "trggers" of
SCD pain episodes and healthcare utilization in the moment of
pain, suggesting targets fortimely care that mutes pain episodes.
Key words: sickle cell disease U ufilization * pain a
epidemiology
© 2005. From the Division of Quality Health Care (Smith, chairman and asso-
ciate professor; Penberthy, assistant professor), Department of Biostatistics
(McClish, associate professor), Department of Psychiatry (Levenson, vice
chairman, professor), Division of Hematology/Oncology (Roberts, associate
director of clinical research/professor), Department of Pathology (Roseff,
associate professor) and Department of Emergency Medicine (Aisiku, assis-
tant professor), Virginia Commonwealth University, Richmond, VA; Depart-
ment of Health Evaluation Sciences, University of Virginia, Charottesville, VA
(Bovbjerg, associate professor); and Department of Psychology, University of
North Carolina at Chapel Hill, Chapel Hill, NC (Gil, professor-clinical
research/chairman). Send correspondence and reprint requests for J NatI
Med Assoc. 2005;97:183-193 to: Wally R. Smith, MD, Virginia Commonwealth
University, Division of Quality Health Care, Box 980306, Richmond, VA 23298;
phone: (804) 828-6938; fax (804) 828-4862; e-mail: wrsmith@vcu.edu
INTRODUCTION
Sickle cell disease (SCD) is a genetic disease well-
known to be manifested by sometimes profound
hemolytic anemia. It may have protean, total-body
manifestations. However, its primary symptomatic
manifestation is acute to subacute paroxysmal
episodes of ischemic pain, known as "painful crises,"
due to red blood cell vaso-occlusion. Crises may
begin as soon as six months after birth and may con-
tinue throughout life. Because of the recurrent and
chronic nature of crises, and patients' often numerous
resultant encounters with the healthcare system due to
crises, SCD presents a significant financial burden on
patients, their families and the healthcare system.
Like many other chronic diseases, SCD is mani-
fested by exacerbations and remissions, resulting ulti-
mately in chronic organ failure and premature death.
But unlike many other diseases, the etiology of SCD
is a genetically mediated production of one or more
aberrant hemoglobins. These aberrant hemoglobins,
including sickle hemoglobin (Hb S), are inherited as
an autosomal recessive trait. Thus, the most severe
form of SCD, homozygous sickle cell anemia (Hb
SS), occurs when Hb S is inherited from both parents.
In the United States, this happens in about one in 375
African-American births.'-3
Since African Americans are on average poorer,
have more limited access to healthcare services and
die sooner than Caucasians,4 understanding health
services for SCD may yield unique insights into the
relationship between symptoms and illness on one
hand, and access, quality, healthcare utilization and
costs for the poor and underserved on the other. Pain
is the primary symptomatic manifestation of SCD
and the most common reason for presentation to a
medical provider.5 However, pain, manifestations of
pain and proper treatment of pain in adults with
SCD, both acutely and over time, are all poorly
understood.
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A RESEARCH AGENDA FOR
BIOBEHAVIORAL PAIN MANAGEMENT
IN SICKLE CELL DISEASE
Understanding the New Epidemic
of Sickle Cell Disease
An important reason for the poor understanding
of pain in SCD is that adult SCD is a new "epidem-
ic," poorly described epidemiologically. In 1970, the
estimated median survival for patients with SCD
was 20 years, so treating the pain ofSCD was prima-
rily left to those caring for children. Fortunately,
with important advances, such as prophylactic peni-
cillin for children, mortality rates in children have
drastically decreased.6 In one study between 1968
and 1992, rates decreased by 41% for one-to-four-
year-olds, by 47% for five-to-nine-year-olds and by
53% for 10-to-14-year-olds.7 By the 1980s, the fed-
erally funded Cooperative Study of SCD (CSSCD)8
found median survival was into the fourth decade
for homozygous patients; that patients with doubly
heterozygous forms of SCD, such as Hb SC, fared
even better; that higher hematocrit was associated
with more pain; and that higher percentages of per-
sistent fetal hemoglobin (Hb F) were associated with
less severe disease and longevity.
Median SCD survival now stretches well into the
fourth or fifth decade.9 This improved survival has
created the relatively new phenomenon of adults
with chronic SCD. It has also resulted in adult med-
ical professionals treating pain in a disease for
which they have limited training and experience. A
third of patients in one study reported inadequate
pain relief in the hospital, and nearly half reported
long delays in being treated.'10
There is very little evidence-based data on which
to base treatment for the growing population of
adults with SCD. Available epidemiologic data
focuses on the frequency of pain resulting in emer-
gency department (ED) use and hospitalizations for
crisis pain in SCD, and few investigations have char-
acterized the manifestations of SCD outside of tradi-
tional healthcare facilities, or how patients respond
to SCD pain other than by visiting their physician. It
is unknown what percent ofpatients treat their crises
at home versus what percent utilize various health-
care professionals.
Understanding Measures of Pain in
Sickle Cell Disease
Another important reason for the poor under-
standing of pain in SCD is that, other than health-
care utilization, measures of pain in SCD are poorly
developed. Because there is not a trusted, widely
accepted pain measure in SCD that allows commu-
nication between physicians and patients, adults in
particular sense distrust when, during a crisis, they
describe to caregivers the presence, intensity, lack of
relief or recurrence of their pain. Unlike ischemia
due to myocardial infarction or peripheral vascular
disease, to date, ischemic pain due to red blood cell
vaso-occlusion has no observable clinical correlates.
Physicians cannot depend on physical exam or labo-
ratory means to validate subjective descriptions of
painful crises. This may often lead to physician frus-
tration and skepticism of patient reports of pain as
well as both physician and patient dissatisfaction,
particularly when urgent care is provided by a physi-
cian who has never met the patient.
For this reason, we believe the research agenda
will only be advanced by measuring the variability
inpain in SCD on one hand, and response to pain on
the other, simultaneously and independently. This
has not been done in previous large-scale studies,
which have defined and quantified pain crises as
episodes ofhealthcare.
Healthcare utilization as a proxy measure of pain
in SCD is insufficient in several ways. First, bias
could result, because counts ofutilization may under-
estimate the true crisis frequency, by excluding crises
that last only a few hours and may be self-treated.
Anecdotally, many patients tell clinicians they loathe,
and therefore avoid, coming to busy EDs for a painful
crisis and treat even severe pain crises at home. Sec-
ond, bias could result because counts of utilization
may overestimate the true crisis frequency. Multiple
visits (e.g., to the ED) may occur during a single
painful crisis, or utilization not due to crisis pain may
occur. In the CSSCD, utilization episodes that
occurred within a two-week period were counted as
one episode. Seventy-four patients were excluded
from the analyses, because they had "more than 10
closely spaced episodes," making it difficult to deter-
mine an accurate pain rate. Further, nearly 40% of
individuals did not utilize healthcare for a crisis dur-
ing a three-year period.I1
Third, distortion and bias could result because
other factors besides pain may independently influ-
ence healthcare utilization due to crises, distorting
the response to an underlying crisis. For example,
managed care cost- and utilization-containment
pressures are driving down utilization. This has
muddied the relationship between utilization rates
and need for care.
Thus, to better understand pain and the response
to pain in SCD, studies that measure pain and uti-
lization using independent measures are needed.
These studies should compare pain-based crisis
measures with utilization-based crisis measures.
They should demonstrate the percentage of home-
managed crises. They should offer a method of dis-
counting or adjusting for background, chronic pain
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when counting acute crises. Last, they should pro-
pose and refine a biologically based, reproducible
means of comparing SCD pain across studies and
between patients that could be used to determine the
relative effectiveness ofSCD pain interventions.
Table 1. Variables Measured in PiSCES
Category Variables Definition(s) Measurement Instrument(s)
Disease-Related Demographic Age, gender Self-report
Variables Genotype SS, SC, SB1thal, SB3thal, Hemoglobin electrophoresis
Other, % Hb F
Hematologic Hemoglobin, reticulocyte Coulter counter, peripheral
variables count, white cell count, smear
platelet count
Pain and pain Pain intensity (0-9), pain- Daily pain diary
response related distress (0-9), pain-
related interference (0-9),
pain relief (0-9), subjective
report in crisis" (yes/no),
pain location (front/back
body locator charts),
analgesic use (names of
drugs, number of pills),
various healthcare utilization
(yes/no)
Hydroxyurea use Dose, length of Self-report from survey
therapy, benefit
Treatment Usual opiate and opiate Self-report from survey
dose, other medications
including antidepressants
Renal failure Creatinine >1.4 mg/dL Serum chemistries
Proteinuria 4+, or >300 mg/dL Urine dipstick analysis, protein
content
Psychosocial Stress Sickle cell disease- Sickle Cell Disease Stress
Variables specific stressors Questionnaire
Mental health status Score signifying anxiety Prime-MD Patient Health
and/or depression Questionnaire
Coping behaviors Positive coping attempts, Coping Strategies Questionnaire,
negative coping styles Chronic Pain Coping Inventory
Social interactions Low support from significant Multidimensional Scale of
others and friends, negative Perceived Social Support, Test
social interactions of Negative Social Exchange
Cognitive dysfunction Cognitive score <27 (excludes Mini-Mental status exam
from diary collection)
Functional status Fair or poor scale scores Medical Outcomes Study SF-36
Socioeconomic status Lower Index scores, income Hollingshead's two factor index,
<$20,000 self-report from survey
Readiness (to Access Low insurance class, no Self-report from survey




Perceived threat from High scale score RAND Health Outlook
disease questionnaire
Perceived benefits/ Scale score high benefit, RAND Medical Care opinion
barriers to care low barriers questionnaire
Understanding Variables that
Explain Pain in Sickle Cell Disease
To date, only biological and demographic vari-
ables have been well-shown to explain pain variation
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in SCD. These variables explain only part of the
observed variance in crisis frequency.'2 Only now is
knowledge emerging about how other variables may
influence differences in pain responses. It would be
reasonable to test whether SCD, like many other
chronic diseases, conforms to Andersen's healthcare
utilization model'3 or the biopsychosocial model of
illness popularized by Engel'4 and others. Measures
of factors from the psychosocial and environmental
domain may help predict patient pain and response
to pain. Were important predictor variables found, it
would then be reasonable to test interventions that
attempt to alter these predictors.
While a number of studies have explored psy-
chosocial determinants of utilization in SCD,'5-'8
only a few biobehavioral interventions have attempt-
ed to alter pain and utilization in SCD. Vichinsky
and others tested a multifaceted, intense intervention
to improve pain management of sickle cell patients
through counseling and carefully monitored opiate
prescribing. This program reduced ED visits for the
10 patients who suffered chronic pain from 386 to
164, and reduced admissions from 41 to 23 during
sequential six-month periods. It is unclear which
element(s) of this intervention was critical or how
opiate dose influenced utilization.'9
Gil showed that, at three-month follow-up ofa ran-
domized trial, a pain-coping skills intervention in
African-American adults with SCD lowered pain per-
ceptions from a laboratory-induced pain stimulus and
significantly increased coping attempts. Using
prospective daily pain diaries, this study found that on
pain days when subjects used coping strategies, they
had less major healthcare contacts than on pain days
when they did not use coping strategies.20
Other interventions have met with limited success.
Gil showed earlier that a brief training in cognitive
coping skills resulted in increased coping attempts,
decreased negative thinking and lower tendency to
report pain during laboratory-induced noxious stimu-
lation.21 Kaslow reported a family intervention in chil-
dren with some success.22 Dinges used self-hypnosis
as an adjunct to traditional modes of treatment. Self-
hypnosis significantly reduced pain days. Both the
proportion of "bad sleep" nights and the use of pain
medications also decreased significantly during the
self-hypnosis treatment phase.23
Figure 1. Draft conceptual explanatory model of pain and utilization over time in sickle cell disease. |
|l N4hl
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A Conceptual Model of Pain and
Response to Pain in Sickle Cell
Disease
Our emerging SCD research program seeks to
approach SCD and its treatment at the genetic, bio-
logical, clinical, personal and healthcare system lev-
els. We have developed a model of pain and
response to pain in SCD (Figure 1) to serve as a
framework on which to study SCD pain, the most
common clinical manifestation of SCD in adults.
Figure 2. Draft conceptual explanatory model of daily pain, distress, and pain response in sickle cell
disease in two patients.
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The model is informed by a combination ofAnder-
sen's and Engel's above models, by the Health Belief
Model24'25 and by empirical research to date on pain
and response to pain in SCD.
Engel's model suggests that biological, psycho-
logical and social factors all interact to produce
health and/or illness. Andersen's healthcare utiliza-
tion model suggests that all of these factors interact
to produce variability in healthcare utilization. The
Health Belief Model proposes that attitudes reflect-
ing readiness to act determine healthcare behaviors
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when cues to take action are present (e.g., pain). We
have used the framework ofthe Health Belief Model
to review studies relating SCD utilization to psy-
chosocial variables.26
Our model hypothesizes that several classes of
variables act in concert over time to explain pain and
response to pain (the physical response of disability,
the emotional response of distress and the coping
response of healthcare utilization) in SCD. These
predictor variables may cause or relieve pain, which
in turn may provoke disability, distress and/or
increases or decreases in utilization. These predictor
variables may also directly cause utilization. Alter-
Figure 3
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natively or additionally, these predictor variables
may influence the relationship between pain and uti-
lization, as may disability and distress.
Figure 1 shows that psychosocial variables in our
model include stress, mental health status, coping
behaviors and social support. Demographic variables
include age and gender. Disease-related variables
include sickle genotype, hematocrit, percent hemoglo-
bin F, pain location, sickle complications and comor-
bidities. Treatment variables include hydroxyurea,
which not only reduces the frequency ofpainful crises27
but also lowers sickle cell mortality;28 usual opiate and
opiate dose; and other medications, including antide-
pressants. Readiness
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and pain response. In general, we expect pain to be
associated with distress but for the relationship and
the response to be modified by other variables. For
instance, equivalent pain in persons with effective
coping strategies, high levels of family social support
and adequate healthcare access may result in less dis-
tress and lower likelihood of ED or inpatient care,
compared to those with ineffective coping, low sup-
port and poor access to regular care. Similarly, we
expect that early, rapid and effective coping with pain
(e.g., use of nonprescription analgesia, scheduling an
urgent clinic visit, obtaining prescription analgesia)
will blunt increases in pain and also reduce distress,
both through pain reduction and through enhanced
mental well-being resulting from effective coping and
pain response.
Figure 2 illustrates, through two hypothetical
examples, some of the expected temporal relation-
ships among pain, distress due to pain, medication
use and healthcare utilization within the context of
personal, interpersonal and environmental factors.
Ms. Jones, for instance, experiences two pain
episodes within the illustrated 14 days. She has poor
access to healthcare (e.g., no insurance, no primary
care provider), little support from friends and family
(e.g., for transportation), and a history of coping with
pain that focuses on emotions rather than on action.
On about day three, her pain increases steadily, fol-
lowed by increased distress. Without effective sup-
port, coping or access to primary care, her pain and
distress lead to the ED, to which she is transported by
a cousin who happens to be visiting. Her pain sub-
sides after a prescription analgesic, but Ms. Jones
does not keep a follow-up outpatient clinic appoint-
ment, since she cannot afford to pay out ofpocket. On
day seven, her pain increases again. With no way to
get to the hospital, her pain and distress escalate rap-
idly, until she is compelled to seek care, at which time
she is admitted in a severe pain episode.
Another patient, Ms. Baker, also experiences two
periods of elevated SCD pain during the two weeks.
However, during the initial episode, Ms. Baker initi-
ates a round of nonprescription pain relief as soon as
the pain begins and makes a clinic appointment, to
which she is taken by her spouse, as the pain increas-
es. At the visit, analgesia is prescribed, which success-
fully stems the pain. Although her pain is similar to
that of Ms. Jones's initial episode, her more effective
coping and support reduces her distress. During the
second episode, Ms. Baker again recognizes the pain
increase. Because she has been prescribed analgesia
to take as her pain warrants, she is able to stem the
pain without a clinic visit. Though her distress
increases initially, the combination of effective anal-
gesia, support and coping quickly reduces distress.
Summary of Research Agenda
In summary, the research agenda for better under-
standing and managing pain in SCD can be served
best first by gaining a better understanding of the
prevalence of disease and the frequency of pain in
adults with SCD. Second, it is critical to distinguish
pain in SCD from healthcare utilization and other
responses to pain in SCD. Patients, physicians,
researchers, planners and policy makers would all
benefit from this distinction. Third, a measure ofpain
that is acceptable, available and useful to patients and
physicians would, in particular, enhance communica-
tion between physicians and patients. Enhanced com-
munication would be a first important step to a group
of underserved patients receiving better pain relief.
Fourth, it is critical to determine various kinds ofpre-
dictors ofpain and of response to pain in SCD. Treat-
ment could be improved if new, potentially mutable
variables were found that explained pain variability or
variability in response to pain.
Pain in Sickle Cell Epidemiology
Study (PiSCES)
As a step in advancing this research agenda, we
designed and implemented the Pain in Sickle Cell
Epidemiology Study (PiSCES). PiSCES is a longi-
tudinal, etiologic study ofpain in SCD, with particu-
lar emphasis on potentially mutable etiologic, nonbi-
ological variables. It is also a methodological study
of the relationship between pain and the response to
pain in SCD. Using the biopsychosocial model of
Figure 1, PiSCES investigators seek to understand
correlates ofpain and healthcare resource utilization
in adult sickle cell patients and to look for targets for
interventions to improve pain and optimize that uti-
lization. We aim to:
* Measure the temporal patterns ofpain and response
to pain in SCD, including home management.
* Examine the relative importance of biological,
psychological and socioenvironmental variables
in explaining the course ofpain, pain dysfunction
and response to treatment for pain in SCD.
* Elucidate emotions and emotional disturbances,
in addition to depression, (e.g., anger, fear, anxi-
ety) which are associated with SCD, and deter-
mine how these emotions modify the experience
ofpain and the response to pain.
To accomplish these aims, we are building multi-
variate models to explain both within-patient4and
between-patient differences in pain and response to
pain. Table 1 lists the outcome and predictor variables
for PiSCES. Outcomes variables are operationalized
using self-reported pain diaries (described below), col-
lected daily over six months. Predictor variables are
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operationalized using individual variables and summa-
ry scores of scales, obtained from primary data collec-
tion using validated instruments. Predictor variables
are organized into the three classes discussed in our
conceptual model: demographic and disease-related




The study is a prospective cohort of primarily
adults in Virginia with SCD. We are assembling the
cohort from various sources. We are studying each
patient's pain and response to pain for six months.
Patients aged 16 or older with SCD living in any
cities or counties in Virginia are eligible to enroll.
The majority of the patients have come from the
Richmond and Tidewater areas, as these areas have
the highest population ofAfrican Americans. Pedi-
atric patients less than 16 years of age are excluded,
because they are suspected to differ substantially
from adults in both their clinical course and health-
care utilization patterns. Patients on chronic
exchange transfusion are excluded because of
effects on hematologic factors and pain. Patients not
oriented to person, place and time (mini-mental sta-
tus score <27); or unable to answer questions by
telephone are excluded, because of inability to com-
ply with diary completion.
Recruitment, Enrollment and
Compensation
The first of several sources of recruitment is a net-
work of community sites that are members of the
Statewide Sickle Cell Chapters of Virginia Inc. The
second source is the network of clinics, hospitals and
EDs-including our own-around Virginia. The third
source is referrals from patients, health departments,
social services offices and home management care
providers. The fourth source is direct recruiting via
health fairs, universities, targeted mailings (including
physician offices), and radio public service announce-
ments. Ofan estimated 1,000 SCD patients in the state
of Virginia, over 300 eligible participants have been
recruited, with enrollment scheduled to close during
the fall of2004.
Patients identified as potentially eligible for the
study are invited and scheduled for an enrollment
visit, at which informed consent and baseline data
are obtained. The enrollment visit is conducted at
one of two community sites, or one of three geo-
graphically dispersed sickle cell clinics at two aca-
demic medical centers-whichever is most conven-
ient for the patient.
Patients are compensated for their participation
as follows: $10 for entry and exit visits; $1 for each
completed diary during months one to four of the
patient's enrollment; and $1.50 per day for diaries
completed during months five and six. Compensa-
tion only occurs if the diaries are postmarked or
received within three business days.
Data Collection and Management,
Retention
We collect an entry survey, perform one venipunc-
ture for blood analysis and collect urine for urinalysis
at entry. Urine and serum collection are performed by
a central, CLIA-certified laboratory. We repeat this
process at exit, save the mini-mental status exam. We
collect a pain diary every day for six months, inpa-
tient healthcare utilization data from the state hospital
discharge file, and if applicable, cause of death data
from the Virginia Health Department.
The entry survey consists of baseline identifying
and demographic data, and measurement of
explanatory and predictor variables (Table 1). It
takes approximately 40-50 minutes to complete.
After patients complete the entry survey, they are
trained to complete an initial pain diary. They then
enter a period of training and monitoring for up to two
weeks. Consistency ofreceipt ofmailed daily diaries is
recorded daily on a grid in a tracking database.
Returned pain diaries are reviewed closely by research
assistants for completeness and face validity. Patients
who fail to complete diaries consistently or appropri-
ately by visual inspection are retrained. Patients are
contacted if their diaries are three or more days late or
for any information missing on the diaries. When nec-
essary, data have been collected in person by study staff
during participant inpatient hospital stays.
Records of all contacts made are maintained in a
tracking log in the database. In addition, we mail
monthly postcards to encourage all patients to continue
sending diaries on a daily basis. Every month, patients
are compensated based on the number of diaries sent.
Along with their check, a month's supply ofdiaries and
envelopes with reminder instructions for completing
and mailing diaries are sent to active patients.
No patient is dropped from the study for failure
to complete diaries appropriately. We are retaining
in the sample all enrolled patients who complete a
baseline survey. We also accept and record all
patients' diary data, regardless of its timeliness and
the patient's compliance status. We, however, mark
all late diaries as such and are conducting compara-
tive analysis of late vs. timely diaries to determine
the effect oftimeliness on diary reporting.
However, patients are classified by compliance with
diary submission. Specifically, patients whose timely
diary submission rate is satisfactory during each ofthe
six months of the study are referred to as compliant
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patients. In contrast, we refer to recruited, noncompli-
ant patients as those who complete only a baseline sur-
vey and one month (30) or fewer diaries, and to patients
who complete greater than 30 daily diaries but are not
fully compliant as partially compliant patients. We
define attrition not to mean that we cannot use a given
patient in any of the planned outcome analyses, but
rather that we lack data to use a given patient in some
ofthe planned outcome analyses.
At the end of six months of participation in the
study, patients are contacted via telephone or mail to
set up an appointment to complete the exit survey
and lab studies.
Pain Diary
We developed the pain diary for PiSCES to
reflect multiple descriptive aspects ofpain; response
to pain; and the multiple, temporally variable factors
that affect pain in SCD. The pain diary (Figure 3)
asks participants to recall the past 24 hours, reflect-
ing on their worst pain intensity, their response to
pain (i.e., distress, disability, healthcare utilization
and type of utilization), their use of opiate and
nonopiate analgesics, and their bodily sites of pain.
Participants record their pain, distress and disability
on a 0-9 ordinal scale. Separate boxes record
whether participants made a call for a prescription
refill, used nonopiate analgesics, opiate analgesics,
made a scheduled or unscheduled visit to a physi-
cian's office or clinic, or visited an ED or hospital.
Open-ended questions allow patients to write in oth-
er methods of pain relief and behavior modification
techniques. Front and back body locator charts allow
a detailed notation of pain sites beyond central or
peripheral categorization. Pain sites are indicated
using an "X" on as many site blocks as apply, on a
diagram ofthe front and back drawing of a body.
Analyses
All PiSCES analyses will be hypothesis driven,
based on our conceptual model of SCD, previous
exploratory work and other scientifically plausible
underpinnings. Major analyses will consist of both
between-patient and within-patient predictive mod-
els using multivariable regression. Both the within-
patient and between-patient regression models will
predict pain and various types of utilization
episodes, including nonopiate analgesic use, opiate
use, office visits, ED visits and hospitalization.
Within-patient models will determine within-patient
"triggers" of painful episodes, hospitalizations, ED
visits and other utilization events.
The between-patient models will predict mean or
median pain, distress and disability, the number of
painful episodes and the percentage of each patient's
crises that result in various types of utilization. We
will enter the classes of predictor variables in Table
1 simultaneously rather than progressively.
One series ofmodels will predict mean daily pain
during the approximately 188 days of observation.
The second series of models will predict the number
ofcrises each patient experiences during six months.
Pain intensity ratings and diary data will be trans-
formed into pain episode counts. We will explore
several definitions of an episode (crisis). The first
and foremost definition will be one or more consec-
utive days that the box, "I was in a crisis," is checked
on a daily diary. The number ofpainful crises will be
defined as the number of groups of consecutive days
that box is checked. The length of a given painful
crisis will be the number of consecutive days the box
is checked.
For the second definition of a crisis, we will use a
mathematical formula to obtain individualized pain
thresholds that define a painful episode for each patient
based on their daily pain intensity ratings. Each
patient's threshold will be defined as M+1 IQR, or
their median pain intensity for the six months, plus the
square root of the interquartile range of their pain for
the six months. The threshold definition takes into
account differences in pain tolerance and sensitivity as
well as differences in pain stimuli. Several pain loca-
tion patterns may also emerge from descriptive analy-
ses, and though they are outcomes themselves, may
also be predictive of pain response. We will explore
whether locational patterns can define a "crisis.'"
To predict response to pain, we will first build a
series of predictive models to explain the outcome
variable "number of utilization episodes." A utiliza-
tion episode will be defined as a period of consecu-
tive days in which each daily diary has indicated that
an unplanned visit to an MD, ED visit or hospitaliza-
tion has occurred. (An alternative utilization episode
might possible be more narrowly defined to only
include ED visit or hospitalization, or expanded to
include days when opiates have been used.) Next, we
will predict the utilization percentage, or the percent-
age of each patient's painful crises that result in a giv-
en type of utilization. (100% x [number of patient's
painful crises with associated utilization/total number
ofpatient's painful crises]). To measure effects ofpain
location on models of these outcomes, we will enter
as predictor variables any discovered patterns of loca-
tion from the body locator chart.
To conduct within-patient analyses, we will deter-
mine within-patient "triggers" of painful episodes,
hospitalizations, ED visits and other utilization events
by treating each event as an outcome, using a nested
case-crossover design.29 Analysis will consist of con-
ditional logistic regression to relate potential triggers
to the event. Separate analyses will be performed for
each dependent variable, including painful episodes,
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ED use, hospital use and other pain-related utiliza-
tion. Independent, "trigger" variables will include
(change in) pain intensity, pain location, number of
pain sites, disability, distress, treatment and adjunc-
tive relief measures 1-3 days prior to the index event
or control day. One important clinical application of
the result will be the ability to predict crises in ambu-
latory patients and perhaps intervene to abort them.
Importance and Impact:
Advancing the Research Agenda
Results of PiSCES will very likely stimulate
additional etiologic questions regarding pain in SCD
that require further study. For example, if results of
our within-patient, case-crossover study suggest that
pain and subjective pain crises are inherently pre-
dictable using diary data from the days preceding
the crisis, questions may arise regarding subjective
circumstances preceding each patient's crisis.
Other interesting questions arising from clinical
anecdotes include: Were patients aware hours or
days ahead of time that they were going to have a
crisis, similar to the "aura" preceding a grand mal
seizure? If not, might they have become aware by
more detailed self-observation or by attending to
their pain diary scores? If patients were aware of an
impending crisis, did they take measures to abort or
prevent the crisis, such as calling their physician for
pre-emptive intravenous fluids or pain relief, or did
they pursue a complementary and alternative medi-
cine intervention, such as a heating pad, warm baths
or massage, or other strategies to alleviate their pain,
in addition to their home medication?
Further, if results of our case-crossover studies
suggest, as we hypothesize, that medication, ED and
hospital utilization occur for reasons other than
severity of that or the preceding days' pain, distress
or disability, then further case-crossover studies or
qualitative reason-for-visit information could be
illuminating. For example, why did patients choose
to go to the ED rather than stay home and manage
their pain? Applying our conceptual model in Figure
1 suggests that linking such qualitative data to our
already planned quantitative diary data might be
more informative than the quantitative data alone. In
fact, patients may utilize different particular instru-
mental coping strategies on a given day. Further,
acutely changing access issues, such as availability
of childcare, job flexibility and transportation to
care, may influence whether utilization occurs on a
given day. Daily diaries may need to be further aug-
mented to allow reporting of daily changes in these
potential predictors.
In addition to spurring further etiologic studies,
results may prove useful to develop multifactorial inter-
vention studies. Intervention studies would be warrant-
ed if results suggested that several of the collected
mutable variables are important predictors in our multi-
variate predictive models of pain and utilization. An
intervention study could, for example, compare multi-
factorial case management conducted only at health-
care sites to home health-case management similar to
that ofcurrent geriatric home healthcare programs.
In summary, we believe PiSCES will advance
knowledge of the etiology and influences on pain
and pain response in SCD. By revealing potentially
mutable explanatory variables, the study's results
may identify targets of biobehavioral treatment
interventions. The study will also advance methods
of measuring pain and pain response in SCD. By
measuring pain directly, simultaneously with uti-
lization, our results may validate or invalidate prior
studies. Results of this study can be used to
improve diagnosis and treatment of sickle cell pain,
to dispel myths about sickle cell pain and those
who endure it, and to improve the quality of life for
patients with SCD.
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